Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG-L in ITP
NCT00151840Phase 3Completed
- Sponsor
- Prothya Biosolutions
- Start
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Prothya Biosolutions. Primary endpoints: Efficacy of IVIG-L and Safety of IVIG-L. Started Oct 2001; status: completed.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00151840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151840.